0001213900-22-007471.txt : 20220214 0001213900-22-007471.hdr.sgml : 20220214 20220214160049 ACCESSION NUMBER: 0001213900-22-007471 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220210 FILED AS OF DATE: 20220214 DATE AS OF CHANGE: 20220214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aberman Zami CENTRAL INDEX KEY: 0001344740 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31392 FILM NUMBER: 22631064 MAIL ADDRESS: STREET 1: 63 RABUTZKY STREET CITY: RAANANA STATE: L3 ZIP: 43220 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PLURISTEM THERAPEUTICS INC CENTRAL INDEX KEY: 0001158780 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 980351734 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: MATAM ADVANCED TECHNOLOGY PARK STREET 2: BUILDING NO. 5 CITY: HAIFA STATE: L3 ZIP: 3508409 BUSINESS PHONE: 972-74-710-7171 MAIL ADDRESS: STREET 1: MATAM ADVANCED TECHNOLOGY PARK STREET 2: BUILDING NO. 5 CITY: HAIFA STATE: L3 ZIP: 3508409 FORMER COMPANY: FORMER CONFORMED NAME: PLURISTEM LIFE SYSTEMS INC DATE OF NAME CHANGE: 20030701 FORMER COMPANY: FORMER CONFORMED NAME: AI SOFTWARE INC DATE OF NAME CHANGE: 20010906 4 1 ownership.xml X0306 4 2022-02-10 0 0001158780 PLURISTEM THERAPEUTICS INC PSTI 0001344740 Aberman Zami MATAM PARK, BUILDING #5 HAIFA L3 3508409 ISRAEL 1 0 0 0 Common Stock 2022-02-10 4 P 0 80616 1.80 A 91756 I By Rose Hitech Ltd. Common Stock 1493973 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on the Tel Aviv Stock Exchange in New Israeli Shekels (NIS), at per share purchase prices ranging from NIS 5.70 to NIS 5.90, inclusive, or ranging from $1.77 to $1.82 in U.S. Dollars, inclusive (based on an exchange rate of NIS 3.221 per U.S. dollar). The Reporting Person undertakes to provide to Pluristem Therapeutics Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). /s/ Zami Aberman 2022-02-14